465 related articles for article (PubMed ID: 10976656)
1. Clinical pharmacokinetics of slow release mesalazine.
De Vos M
Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
[TBL] [Abstract][Full Text] [Related]
2. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
3. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
Prakash A; Markham A
Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
[TBL] [Abstract][Full Text] [Related]
4. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
5. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Tromm A; Griga T; May B
Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
[TBL] [Abstract][Full Text] [Related]
6. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
Sandborn WJ; Hanauer SB
Aliment Pharmacol Ther; 2003 Jan; 17(1):29-42. PubMed ID: 12492730
[TBL] [Abstract][Full Text] [Related]
7. Review article: aminosalicylates in inflammatory bowel disease.
Hanauer SB
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():60-5. PubMed ID: 15352896
[TBL] [Abstract][Full Text] [Related]
8. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
Mahmud N; Weir DG; Kelleher D
Ir J Med Sci; 1999; 168(4):228-32. PubMed ID: 10624358
[TBL] [Abstract][Full Text] [Related]
9. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment.
Frieri G; Pimpo MT; Palumbo GC; Onori L; Viscido A; Latella G; Galletti B; Pantaleoni GC; Caprilli R
Aliment Pharmacol Ther; 1999 Nov; 13(11):1413-7. PubMed ID: 10571596
[TBL] [Abstract][Full Text] [Related]
10. Review article: Oral, modified-release mesalazine formulations--proprietary versus generic.
Forbes A; Cartwright A; Marchant S; McIntyre P; Newton M
Aliment Pharmacol Ther; 2003 May; 17(10):1207-14. PubMed ID: 12755834
[TBL] [Abstract][Full Text] [Related]
11. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
Brogden RN; Sorkin EM
Drugs; 1989 Oct; 38(4):500-23. PubMed ID: 2684592
[TBL] [Abstract][Full Text] [Related]
12. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.
Nugent SG; Kumar D; Rampton DS; Evans DF
Gut; 2001 Apr; 48(4):571-7. PubMed ID: 11247905
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet.
Wilding IR; Kenyon CJ; Hooper G
Aliment Pharmacol Ther; 2000 Feb; 14(2):163-9. PubMed ID: 10651656
[TBL] [Abstract][Full Text] [Related]
14. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
Mulder CJ; van den Hazel SJ
Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596
[TBL] [Abstract][Full Text] [Related]
15. Mesalazine for the treatment of inflammatory bowel disease.
Criscuoli V; Modesto I; Orlando A; Cottone M
Expert Opin Pharmacother; 2013 Aug; 14(12):1669-78. PubMed ID: 23767798
[TBL] [Abstract][Full Text] [Related]
16. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.
Thomson AB
Aliment Pharmacol Ther; 1991 Oct; 5(5):449-70. PubMed ID: 1793778
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers.
Gionchetti P; Campieri M; Belluzzi A; Boschi S; Brignola C; Miglioli M; Barbara L
Aliment Pharmacol Ther; 1994 Oct; 8(5):535-40. PubMed ID: 7865646
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease.
Wiersma H; Escher JC; Dilger K; Trenk D; Benninga MA; van Boxtel CJ; Taminiau J
Inflamm Bowel Dis; 2004 Sep; 10(5):626-31. PubMed ID: 15472525
[TBL] [Abstract][Full Text] [Related]
19. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
Hanauer SB
Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():37-40. PubMed ID: 16961743
[TBL] [Abstract][Full Text] [Related]
20. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]